Revaclear dialyzers: are optimized for efficient high-flux hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

DIALYZERS ARE OPTIMIZED FOR HEMODIALYSIS (HD) AND PROVIDE REMOVAL OF A SIGNIFICANT NUMBER OF SMALL UREMIC MOLECULES, AS WELL AS MEDIUM-SIZED MOLECULES WITH A SMALLER MEMBRANE-TO-BLOOD CONTACT AREA. A RANDOMIZED CONTROLLED TRIAL HAS DEMONSTRATED THAT THE EFFICACY OF DIALYSIS USING REVACLEAR WAS COMPARABLE TO THE EFFICACY ACHIEVED WITH THE USE OF PROPERLY SIZED FRESENIUS MEDICAL CARE'S FX DIALYSERS [1]. ACCORDING TO THE RESULTS OF A COMPARATIVE CLINICAL STUDY OF REVACLEAR AND FX CORDIAX DIALYZERS, THE INTERNAL DIAMETER OF THE PORACTON MEMBRANE OF THE REVACLEAR DIALYZER - 190 μм, PROVIDES EFFECTIVE INTERNAL FILTRATION IN STANDARD HD WITH BETTER ß2-MICROGLOBULIN CLEARANCE [2]. DURING DIALYSIS USING THE REVACLEAR DIALYZER, AN EFFECTIVE CLEARANCE OF HEPCIDIN REGULATING IRON METABOLISM, WHICH WAS RECENTLY RECOGNIZED AS UREMIC TOXIN, WAS DEMONSTRATED [3]. DUE TO THE SPECIAL DESIGN OF THE BOX/COLLEKTOR AND THE HOLLOW FIBER MEMBRANE OF REVACLEAR DIAlYZERS, RHEOLOGY AND HYDRODYNAMICS CREATED SIMPLIFY THE USE OF THE DIALYZER. THIS ALLOWS TO REDUCE THE DIALYSIS FLUID FLOW TO THE BLOOD FLOW RATIO WITHOUT CHANGING THE DIALYSIS DOSE, WHICH IN TURN CAN HELP REDUCE THE VOLUME OF WATER USED DURING DIALYSIS. THE REVACLEAR DIALYZER AND CLINICAL RESULTS OF ITS USE ARE SUPERIOR TO THE USIAL RESULTS OBSERVED WITH HIGH-FLOW HEMODIALYSIS. THE REVACLEAR DIALYZER IS EFFECTIVE AND ECONOMIC FOR A DIALYSIS CLINIC AND EXPANDS THE POSSIBILITIES OF EFFECTIVE HD IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD).

Full Text

Restricted Access

About the authors

L. -G Nilsson

Research center "Gambro Lundia AB"

W. Beck

Research center "Gambro Lundia AB"

J. Bosch

Research center "Gambro Lundia AB"

References

  1. Mauric A., Haug U., Enzinger G., Kern-Derstvenscheg E., Sluga A., Ausserwinkler C., Beck W., RosenkrantzA.R. Clinical performance comparison of Revaclear™ dialyzer versus larger-surface area dialyzer. ERA-EDTA. 2013, Congress Abstract. SP401.
  2. Von Albertini B., Mathieu C., Cherpillod A., Bösch A., Romo M. New generation of high-flux dialyzers: In-vivo quantification of small- and large-size solute transport in high-ßux HD&HDF. Poster presentation at Swiss Society of Nephrology 2012 Annual Congress.
  3. Zaritsky J., Young B., Gales B., Wang H.J., Rastogi A., Westerman M., Nemeth E., Ganz T., Salusky LB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol. 2010; 5(6): 1010-1014.
  4. Tattersall J., Canaud B., Heimburger 0., Pedrini L., Schneditz D., Van Biesen W., European Renal Best Practice advisory Board. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol. Dial. Transplant. 2010; 25: 1230-1232.
  5. Ronco C., Crepaldi C., Brendolan A. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol. Dial. Transplant. 2003; 18(7) vii 10-vii20.
  6. Gambro Patent Application W02010/020384.
  7. Ward R.A., Greene T., Hartmann B., Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hémodiafiltration. Kidney Int. 2006; 69(8): 1431-1437.
  8. Ward R.A., Idoux J.W., Hamdan H., Ouseph R., Depner T.A., Golper T.A. Dialysate flow rate and delivered Kt/Vurea for dialyzers with enhanced dialysateflow distribution. Clin. J. Am. Soc. Nephrol. 2011; 6(9): 2235-2239.
  9. Leypoldt J.K., Cheung A.K., Agodoa L.Y., Daugirdas J.T., Greene T., Keshaviah P.R. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney Int. 1997; 51: 2013-2017.
  10. Eloot S., Vanholder R., Van Biesen W., Lameire N. The patient as a limit to dialysis technology. Clin. J. Am. Soc. Nephrol. 2011; 6(9): 2105-2107.
  11. Teatini U., Steckiph D., Romei Longhena G. Evaluation of a new online hémodiafiltration mode with automated pressure control of convection. Blood Purif. 2011; 31(4): 259-267.
  12. Cheung A.K., Rocco M.V., Yan G. for НЕМО Study Group. Serum ß2-microglobulin levels predict mortality in dialysis patients: results of the НЕМО Study. J. Am. Soc. Nephrol. 2006; 17: 546-555.
  13. Ouseph R., Hutchison C.A., Ward R.A. Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers. Nephrol. Dial. Transplant. 2008; 23: 1704-1712.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies